Lenacapavir is a long-acting antiretroviral medicine that has introduced a fundamentally different approach to HIV prevention. Unlike traditional oral pre-exposure prophylaxis (PrEP), which requires regular pill-taking, lenacapavir for HIV prevention is administered as a subcutaneous injection every six months after an initial loading regimen.
Its importance lies not only in its high effectiveness, but also in its potential to address some of the practical barriers that have limited consistent use of daily HIV prevention medicines, including pill fatigue, stigma, privacy concerns and difficulty maintaining daily adherence. Lenacapavir therefore represents a long-acting PrEP strategy in which maintaining drug levels in the body replaces the need for daily oral dosing.
What is lenacapavir?
Lenacapavir is a long-acting antiretroviral drug belonging to a relatively new class of medicines known as HIV-1 capsid inhibitors. The HIV capsid is the protein shell surrounding the virus’s genetic material and several viral enzymes. Rather than targeting the enzymes traditionally targeted by many HIV medicines, lenacapavir attaches directly to the capsid and interferes with several stages of the HIV life cycle.
Lenacapavir is particularly notable because it can remain in the body for a prolonged period following subcutaneous administration. The formulation used for PrEP is designed to provide protective drug exposure for approximately six months, meaning that a person does not need to remember to take a prevention pill every day.
For HIV prevention, the drug is marketed in the United States as Yeztugo. Lenacapavir is also marketed as Sunlenca for a different purpose: treatment of HIV infection in heavily treatment-experienced adults with multidrug-resistant HIV, where it is used in combination with other antiretroviral medicines. The two indications should not be confused.
How does lenacapavir prevent HIV?
Lenacapavir works by attacking HIV at the level of the viral capsid, which is an important structural component of HIV. This mechanism is unusual because the drug can interfere with multiple stages of HIV replication rather than focusing on only one viral enzyme. After HIV enters a susceptible cell, the virus needs to transport its genetic material into the cell nucleus. Lenacapavir interferes with capsid-mediated nuclear transport and prevents interactions between the capsid and cellular proteins needed for efficient nuclear import.
The drug also acts later in the viral life cycle. It interferes with the production and assembly of new virus particles by affecting Gag and Gag-Pol functions. In addition, it disrupts normal capsid formation, producing abnormal viral capsids that cannot function properly. This multi-stage activity helps explain why lenacapavir is pharmacologically different from many established antiretroviral drugs.
Instead of simply blocking one viral enzyme, it interacts directly with the capsid and disrupts several essential processes. That distinction is important because HIV is highly adaptable. Drugs that act at different stages of the viral life cycle provide additional tools for preventing and treating infection, although lenacapavir resistance remains an important clinical concern.
Lenacapavir for HIV prevention versus HIV treatment
One of the most important points to understand is that lenacapavir for PrEP is a prevention medicine, not a treatment for people who already have HIV. It’s meant to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV. A person must be confirmed HIV-negative before starting it.
By contrast, lenacapavir sold as Sunlenca is used as part of combination treatment for certain people who already have HIV, particularly heavily treatment-experienced adults with multidrug-resistant HIV. Treatment requires other antiretroviral medicines rather than relying on lenacapavir alone. This distinction matters because taking lenacapavir as PrEP when someone already has undiagnosed HIV can create a resistance problem. Consequently, HIV testing is an essential component of the prevention programme.
How is lenacapavir given?
The dosing schedule is one of lenacapavir’s most distinctive features. Following the initial loading regimen, the prevention formulation is administered once every six months. Initiation consists of a 927 mg subcutaneous injection on Day 1, together with two 300 mg tablets, followed by another two 300 mg tablets on Day 2.
Thereafter, the person receives a 927 mg subcutaneous injection every 26 weeks, with a permitted window of approximately two weeks before or after the scheduled date. The injection is given subcutaneously, meaning into the tissue beneath the skin rather than directly into a vein or muscle. The complete injection dose consists of two injections.
The initial oral doses are important because they establish appropriate drug exposure while the long-acting injection begins providing sustained concentrations. The complete initiation schedule is required because the efficacy of the approved prevention regimen was established using that dosing schedule.
Why six-monthly PrEP is significant
The traditional model of PrEP relies heavily on adherence. Even highly effective medicines cannot provide their intended protection if people do not take them consistently. Daily medication can be difficult for some people to maintain. A person may forget doses, travel, experience disruptions in routine, worry about someone discovering their pills, or simply become tired of taking medication every day.
Lenacapavir changes this equation. Instead of requiring 365 prevention-pill decisions a year, the person generally needs two injection visits per year after initiation. WHO has specifically highlighted the potential of long-acting lenacapavir to address barriers associated with daily pill-taking, stigma and access to HIV prevention. The organization recommends it as an additional PrEP choice rather than as a replacement for all other prevention methods.
The distinction between efficacy and effectiveness in real-world use is important here. A medicine can be highly efficacious under clinical-trial conditions, but its real-world impact depends partly on whether people can and will use it correctly. The six-month dosing schedule is intended to make sustained prevention easier.
How effective is lenacapavir against HIV?
Clinical trials have produced exceptionally strong results for twice-yearly lenacapavir PrEP. The PURPOSE 1 trial evaluated lenacapavir in adolescent girls and young women in South Africa and Uganda. Among 2,134 participants who received lenacapavir, no HIV infections occurred during the primary analysis period. By comparison, infections occurred among participants receiving daily oral PrEP regimens.
The study recorded 55 HIV infections across the relevant trial groups: zero among the 2,134 participants assigned to lenacapavir, 39 among 2,136 participants receiving daily emtricitabine-tenofovir alafenamide, and 16 among 1,068 participants receiving daily emtricitabine-tenofovir disoproxil fumarate. The researchers reported that HIV incidence with lenacapavir was significantly lower than both estimated background incidence and incidence in the TDF/FTC group.
The PURPOSE 2 trial extended the evidence to cisgender men, transgender women, transgender men and gender-nonbinary people who have sex with men. Among 3,265 participants included in the primary analysis, two HIV infections occurred in the lenacapavir group compared with nine in the daily TDF/FTC group. The incidence in the lenacapavir group was 96% lower than estimated background HIV incidence and significantly lower than the incidence observed with daily TDF/FTC.
The CDC subsequently characterized the evidence from these trials as high-certainty evidence and reported efficacy of 100% against the estimated background incidence in the PURPOSE 1 population and 96% in the primarily male PURPOSE 2 population over approximately 52 weeks. These figures should not be interpreted as meaning that HIV acquisition is mathematically impossible for every individual receiving lenacapavir. Clinical-trial results describe what happened in particular study populations under specified conditions. Continued HIV testing and adherence to the injection schedule remain essential.
Who can use lenacapavir PrEP?
Eligibility depends on national regulations and clinical guidance, so people should be assessed by a qualified healthcare professional rather than assuming that lenacapavir is appropriate for everyone. Ideally, it’s intended for adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV-1 and who have confirmed negative HIV status. People who may benefit from PrEP generally include individuals whose sexual or epidemiological circumstances create a meaningful possibility of HIV acquisition.
Risk assessment can consider factors such as a sexual partner’s HIV status and viral suppression, local HIV prevalence, sexual networks, condom use, previous sexually transmitted infections and other circumstances. PrEP is not restricted to one gender or sexual orientation. The PURPOSE trials provided evidence across several populations, while national programmes may determine eligibility and priority populations according to local epidemiology.
Why HIV testing is essential before every injection
HIV testing is arguably the most important safety requirement associated with lenacapavir PrEP. A person should not start lenacapavir if they already have HIV infection. If HIV is acquired before treatment is started or during PrEP, administering a long-acting drug without recognizing the infection can expose the virus to prolonged concentrations of lenacapavir without providing a complete HIV treatment regimen. This creates an opportunity for drug-resistant HIV to emerge.
HIV testing is required before initiation and before subsequent injections, with additional testing when clinically appropriate. WHO emphasizes HIV testing for people initiating or continuing long-acting injectable PrEP and supports the use of rapid diagnostic testing approaches to facilitate access. This is one reason lenacapavir PrEP should be delivered through an appropriate healthcare programme rather than treated as an ordinary injection that can be administered without screening.
What happens if someone misses an injection?
The six-monthly schedule is an advantage, but it also creates an important responsibility: appointments need to be maintained. The injection should be given every 26 weeks with a two-week window on either side of the scheduled date. If a delay of more than two weeks is anticipated, oral lenacapavir tablets can be used temporarily under the approved regimen until injections resume.
If more than 28 weeks have passed since the previous injection and the person has not been taking the recommended oral medication, the prescribing information provides a restart regimen that includes the initial loading schedule when clinically appropriate. This is particularly important because lenacapavir is extremely long-acting.
Drug concentrations decline gradually rather than disappearing immediately when the scheduled injection date passes. A healthcare provider should therefore determine the appropriate response to a delayed or missed injection, especially if there has been potential HIV exposure during the period of inadequate drug coverage.
The importance of the long “tail”
The prolonged persistence of lenacapavir in the body is simultaneously one of its greatest advantages and one of its important clinical considerations. After the injection, lenacapavir concentrations decline slowly. Residual concentrations can remain in systemic circulation for 12 months or longer.
This prolonged pharmacological “tail” means that stopping injections does not cause the drug to disappear immediately. That matters because a person who stops receiving injections can eventually reach drug concentrations that are too low to reliably prevent HIV but still high enough to exert selective pressure on HIV if infection occurs.
This is one reason clinicians need to discuss continued prevention and appropriate follow-up when someone discontinues lenacapavir. Stopping PrEP is therefore not simply a matter of missing an appointment and forgetting about the medicine. A healthcare professional should help determine an appropriate transition to another effective HIV prevention strategy where necessary.
What are the side effects of lenacapavir?
The most characteristic adverse effects are associated with the injection site. In PURPOSE 1, injection-site reactions occurred more frequently among people receiving lenacapavir than among participants receiving placebo injections. Most were not serious, although injection-site reactions can include nodules, pain, swelling, redness or other local changes.
Injection-site reactions, headache and nausea are among the most common adverse reactions associated with lenacapavir. Injection-site nodules deserve particular attention because the medication is formulated to remain at the injection site and release slowly. A lump or other local change may therefore persist for some time.
Most injection-site reactions are not medically dangerous, but severe or unusual reactions should be assessed by a healthcare professional. The injection must also be administered correctly. Improper administration into the skin rather than the intended subcutaneous tissue has been associated with serious injection-site reactions.
Does lenacapavir cause HIV?
Lenacapavir itself does not cause HIV. The concern is different: if a person becomes infected with HIV while taking lenacapavir PrEP, the virus may develop resistance to lenacapavir. Resistance occurs because HIV can mutate while replicating. When a person has HIV but receives an incomplete antiretroviral regimen, drug pressure can favor viral variants capable of surviving the medicine. This is why HIV testing is central to lenacapavir PrEP and why anyone diagnosed with HIV while receiving it needs to transition promptly to a complete HIV treatment regimen.
Resistance findings have already been observed in the clinical-development programme. The NIH notes that two participants in PURPOSE 2 who acquired HIV while receiving lenacapavir developed the N74D capsid resistance mutation. The existence of resistance does not mean lenacapavir is unsuitable for prevention. Rather, it highlights why accurate HIV diagnosis, appropriate dosing and careful follow-up are essential components of the prevention strategy.
Does lenacapavir protect against other sexually transmitted infections?
No. Lenacapavir PrEP is designed to prevent HIV-1 infection. It does not provide protection against sexually transmitted infections such as gonorrhea, chlamydia, syphilis, genital herpes or human papillomavirus. It also does not prevent pregnancy. For this reason, HIV prevention should remain part of a broader sexual-health strategy. Condoms, STI screening, vaccination where appropriate, contraception and other prevention measures may remain important depending on an individual’s circumstances.
Lenacapavir and pregnancy
Pregnancy requires individualized clinical consideration. People who are pregnant, planning pregnancy or breastfeeding should therefore discuss lenacapavir with a healthcare professional familiar with HIV prevention and pregnancy rather than making a decision based solely on general information about the drug. The important point is that pregnancy does not automatically mean that HIV prevention is unnecessary. On the contrary, preventing HIV acquisition during pregnancy remains an important public-health and maternal-health objective.
Drug interactions with lenacapavir
Lenacapavir can interact with other medicines, and its long-acting nature makes drug-interaction assessment particularly important. Prescribing information includes specific guidance concerning strong and moderate CYP3A inducers. Some medicines can increase the metabolism or otherwise alter exposure to lenacapavir, potentially affecting its effectiveness. Dose modifications or supplemental doses may be required in certain circumstances.
People receiving lenacapavir should therefore tell their healthcare provider about prescription medicines, over-the-counter medicines, herbal products and other substances they use. This is especially important when starting a new medication during the six-month period between injections. A person should not assume that a medicine is compatible simply because it has been taken safely with other HIV prevention drugs.
How does lenacapavir compare with daily oral PrEP?
The principal difference is the dosing model. Daily oral PrEP requires regular pill-taking, while lenacapavir requires an injection every six months following the initial loading regimen. Both approaches are based on antiretroviral prevention, but they address adherence in different ways. For some people, daily pills are convenient and preferable.
Oral PrEP is well established and remains an important component of HIV prevention. For others, taking a tablet every day may be difficult or undesirable. Lenacapavir offers an alternative for people who prefer less frequent dosing or who encounter barriers associated with daily oral medication. The PURPOSE trials also illustrate an important point about adherence.
In PURPOSE 1, adherence to the oral comparator regimens was relatively low, while the injection was administered as part of scheduled clinical visits. The practical benefit of lenacapavir therefore goes beyond the pharmacology of the drug itself. A six-monthly intervention can change the daily behavior required to maintain prevention.
Lenacapavir compared with cabotegravir
Lenacapavir is not the first long-acting injectable HIV PrEP medicine. Cabotegravir long-acting injection is another established injectable PrEP option, but it requires administration considerably more frequently than lenacapavir. WHO recommends long-acting cabotegravir as an HIV prevention option. Lenacapavir’s distinguishing characteristic is its twice-yearly dosing.
This difference can have practical consequences for people living far from healthcare facilities, people with demanding work schedules, individuals who find frequent clinic visits difficult, and people who prefer greater discretion. The most appropriate PrEP option ultimately depends on individual circumstances, availability, clinical eligibility and personal preference.
Lenacapavir and HIV prevention in Africa
The significance of lenacapavir is particularly relevant to sub-Saharan Africa because several countries continue to experience substantial HIV transmission. PURPOSE 1 was conducted among adolescent girls and young women in South Africa and Uganda, populations for whom HIV prevention remains an important public-health priority. The trial demonstrated the ability of twice-yearly lenacapavir to prevent HIV acquisition in the study population.
WHO subsequently recommended lenacapavir as an additional PrEP option globally, emphasizing that long-acting prevention could help address adherence, stigma and healthcare-access barriers. The potential public-health impact is therefore broader than simply adding another medicine to the PrEP catalogue. It creates another way of delivering prevention to people who may not use daily oral PrEP consistently or comfortably.
What lenacapavir means for HIV prevention
The arrival of lenacapavir represents a broader change in the philosophy of HIV prevention. For many years, prevention programmes have depended heavily on daily oral medicines, condoms, behavioral interventions, HIV testing and other approaches. These tools remain valuable. The challenge has been that prevention must fit into people’s real lives.
A person can understand the importance of PrEP and still struggle to take a tablet every day. Another person may worry about privacy. Someone else may travel frequently or have an unpredictable routine. Long-acting prevention attempts to shift some of the burden away from daily behavior and toward periodic healthcare visits.
WHO’s recommendation is therefore significant not simply because lenacapavir is highly effective in clinical trials, but because it expands the range of choices available to people seeking HIV prevention. WHO specifically recommends offering it as an additional option within combination HIV prevention programmes.
Limitations and unanswered questions
Despite its remarkable clinical-trial performance, lenacapavir does not eliminate every challenge associated with HIV prevention. First, people must return for injections on schedule. The medicine is long-acting, but protection cannot simply be assumed indefinitely after one dose. Second, HIV testing remains essential because infection acquired around the time of initiation or during PrEP can create resistance concerns. Third, access and affordability will influence the drug’s public-health impact.
A highly effective medicine cannot prevent infections at population level if people who could benefit cannot obtain it. Fourth, long-term real-world data will continue to be important. Clinical trials provide strong evidence of efficacy and safety, but national programmes need ongoing surveillance to understand uptake, persistence, resistance, adverse events and implementation challenges. Finally, HIV prevention remains multifaceted. Lenacapavir does not prevent other STIs or pregnancy and should not be viewed as a replacement for every other prevention intervention.
Is lenacapavir a vaccine?
No. Lenacapavir is not an HIV vaccine. A vaccine works by stimulating the immune system to develop protective immune responses. Lenacapavir instead works as an antiretroviral medicine that remains in the body and directly interferes with HIV replication. This distinction is important because lenacapavir’s protection depends on maintaining appropriate drug concentrations. It does not train the immune system to permanently recognize and eliminate HIV.
Can lenacapavir cure HIV?
Lenacapavir is not a cure for HIV. The prevention formulation is intended to stop HIV from establishing infection in people who are HIV-negative. The treatment formulation is used in combination with other antiretroviral medicines to treat certain people already living with HIV. Modern HIV treatment can suppress the virus to very low levels and allows many people living with HIV to lead long and healthy lives, but lenacapavir should not be described as a standalone cure.
The future of lenacapavir
Lenacapavir is likely to remain an important part of the rapidly evolving long-acting HIV medicine landscape. Its six-monthly administration represents a major change from daily oral prevention. The PURPOSE 1 and PURPOSE 2 trials demonstrated strong efficacy across different populations, and WHO and the CDC have incorporated the medicine into their HIV prevention guidance.
Future research will help answer important questions about long-term use, resistance, pregnancy, implementation, access, delivery models and population-level impact. There is also continuing research into other long-acting antiretroviral strategies, meaning lenacapavir is part of a broader movement toward reducing the frequency with which people need to take HIV medicines.
Conclusion
Lenacapavir represents one of the most important developments in HIV prevention in recent years because it combines a novel mechanism of action with an unusually long duration of protection. Instead of requiring a person to remember a prevention pill every day, the approved PrEP regimen uses an initial loading schedule followed by an injection approximately every six months.
Clinical trials involving different populations demonstrated very high efficacy, including zero infections in the primary PURPOSE 1 lenacapavir group and a 96% reduction in HIV incidence compared with estimated background incidence in PURPOSE 2. At the same time, lenacapavir should not be regarded as a standalone solution to HIV.
Regular HIV testing, adherence to the injection schedule, appropriate management of missed doses, attention to drug interactions and monitoring for resistance remain essential. The medicine also does not protect against other sexually transmitted infections or pregnancy. The wider significance of lenacapavir lies in choice.
HIV prevention works best when people have practical options that fit their circumstances. Daily oral PrEP, condoms, injectable cabotegravir, lenacapavir and other prevention strategies can play complementary roles. WHO’s recommendation of twice-yearly lenacapavir as an additional PrEP option, marks a move toward more flexible and long-acting HIV prevention.
For anyone considering lenacapavir, the most important step is to consult a qualified healthcare provider. The drug’s effectiveness depends not only on its powerful antiviral activity, but also on correct HIV testing, appropriate dosing, timely follow-up and integration into a broader HIV and sexual-health prevention strategy.
